Life Sciences Market Research Report
Report Filter Reset All
Sort By Price
Published Date
Category
Publishers
Report Type
Continents
Regions
Global Acute Intermittent Porphyria Drugs Market Insights, Forecast to 2025
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic dis...
$3,900.00 22 May, 2019 | QYResearch
Global Acute Intermittent Porphyria Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant met...
Global Acute Intermittent Porphyria Treatment Market Insights, Forecast to 2025
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic dis...
$3,900.00 22 May, 2019 | QYResearch
Global Acute Intermittent Porphyria Treatment Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant met...
Global Acute Intermittent Porphyria Therapeutics Market Insights, Forecast to 2025
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant metabolic dis...
$3,900.00 22 May, 2019 | QYResearch
Global Acute Intermittent Porphyria Therapeutics Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Acute intermittent porphyria (AIP), also called Swedish porphyria, pyrroloporphyria, intermittent acute porphyria) is a rare autosomal dominant met...
Global Swedish Porphyria Drugs Market Insights, Forecast to 2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deamina...
$3,900.00 22 May, 2019 | QYResearch
Global Swedish Porphyria Drugs Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinog...
Global Swedish Porphyria Treatment Market Insights, Forecast to 2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deamina...
$3,900.00 22 May, 2019 | QYResearch
Global Swedish Porphyria Treatment Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinog...
Global Swedish Porphyria Therapeutics Market Insights, Forecast to 2025
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinogen deamina...
$3,900.00 22 May, 2019 | QYResearch
Global Swedish Porphyria Therapeutics Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Swedish porphyria is a rare autosomal dominant metabolic disorder affecting the production of heme resulting from a deficiency of the porphobilinog...
Global Nelarabine Market Insights, Forecast to 2025
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Nelarabine market is valued at xx million US$ in 2018 and will reac...
$3,900.00 22 May, 2019 | QYResearch
Global Nelarabine Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Nelarabine market is valued at xx million US$ in 2018 and...
Global Arranon Market Insights, Forecast to 2025
Arranon is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Arranon market is valued at xx million US$ in 2018 and will reach xx m...
$3,900.00 22 May, 2019 | QYResearch
Global Arranon Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Arranon is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Arranon market is valued at xx million US$ in 2018 and will ...
Global Atriance Market Insights, Forecast to 2025
Atriance is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Atriance market is valued at xx million US$ in 2018 and will reach xx...
$3,900.00 22 May, 2019 | QYResearch
Global Atriance Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Atriance is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. The global Atriance market is valued at xx million US$ in 2018 and wil...
Global Inotuzumab Ozogamicin Market Insights, Forecast to 2025
Inotuzumab ozogamicin is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The global Inot...
$3,900.00 22 May, 2019 | QYResearch
Global Inotuzumab Ozogamicin Market Insights, Forecast to 2025
$3,900.00 | 22 May, 2019 | QYResearch
Inotuzumab ozogamicin is an antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). The g...
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
